 AnaptysBio is a 675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology. AnaptysBio has 7 clinical-stage therapeutics: 4 wholly-owned including the promising Imsidolimab Phase 2 and the not-so-promising Etokimab Phase 2, as well as one GSK-therapeutic expected to get approval in 4Q 2020. 